BIOHIT GROUP INTERIM REPORT Q2/2014 Biohit Oyj Interim

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
BIOHIT GROUP INTERIM REPORT Q2/2014

Biohit Oyj Interim Report, 21 August 2014 at 9:30 am local time (EEST)

SUMMARY

January–June / H1 2014

  • Net sales grew by 50.9% compared with H1/2013
  • Net sales EUR 2.0 million (EUR 1.4 million)
  • Operating result, continuing operations EUR -2.4 million (EUR -3.4 million)
  • Result for the reporting period, continuing operations EUR -2.3 million (EUR -3.5 million)
  • Result for the reporting period, discontinued operations EUR 3.3 million (EUR 0.0 million)
  • Total result for the reporting period EUR 1.0 million (EUR -3.5 million)
  • Net sales from international operations 90.1% (83.7%) of total net sales
  • Equity ratio 84.7% (80.3%)

April–June / Q2 2014

  • Net sales grew by 39.3% compared with Q2/2013
  • Net sales EUR 1.1 million (EUR 0.8 million)
  • Operating result, continuing operations EUR -1.3 million (EUR -2.4 million)
  • Result for the reporting period, continuing operations EUR -1.3 million (EUR -2.5 million)
  • Result for the reporting period, discontinued operations EUR 0.0 million (EUR 0.0 million)
  • Total result for the reporting period EUR -1.3 million (EUR -2.5 million)
  • Net sales from international operations 89.5% (86%) of total net sales
  • Equity ratio 84.7% (80.3%)

PRESIDENT & CEO SEMI KORPELA:

'During the second quarter of 2014, our net sales grew by 39.3% year on year. In business operations, we focused on supporting our international distributor network, investing in clinical research, and preparing for new product launches.

We started two clinical trials for prevention of migraine-type headache attacks, testing the efficacy of Acetium® capsule in novel clinical indications. The purpose of the trial is to assess the effect of Acetium® capsule in prevention of headache attacks   among patients suffering from migraine or cluster/Horton headache. Both studies will be conducted as multi-center clinical trials in collaboration with Terveystalo Oy and Aava Medical Center altogether in six cities in Finland.

New Acetium® research results were introduced in the major international meeting for gastroenterologists (Digestive Disease Week) in Chicago. The Congress examined Acetium® capsule results from the studies carried out in Japan and Sweden, which confirmed the earlier results of Acetium® studies. The studies found that Acetium® binds 60 to 80 % of Group I carcinogen acetaldehyde, forming a harmless compound that is excreted from the body. The results are clinically highly significant, since carcinogenic DNA-changes caused by acetaldehyde increase exponentially in increasing acetaldehyde concentrations. Based on the results, manuscripts will be written for their publication in international scientific journals.

The conference also heard the results of an Italian study, which has found Acetium® capsule to improve the condition of the gastric mucosa in patients diagnosed with anacidic stomach (atrophic gastritis) caused by a Helicobacter pylori infection or autoimmune disease. This study involved the next stage of an earlier trial, announced by Biohit in September 2013, with a larger number of patients and a longer treatment period. Based on these results, Biohit will launch a completely new controlled double-blind clinical study with a research team consisting of Italian and German scientists. The new study will assess the efficacy of Acetium® capsules in recovering from atrophic gastritis in a sample of 120 biopsy-confirmed patients.

During the reporting period, we continued to expand our distributor network. Bestbion dx GmbH was appointed as a quick tests distributor in Germany, Gulfmed Egypt was appointed as a quick tests distributor in Egypt and Gulf Orlando Medical Co. was appointed as a quick tests distributor in Kuwait. Aloris Vital, S.r.o. was appointed our diagnostics distributor in Slovakia and the Czech Republic. Ildengun Khoshuu Co., LTD was appointed the distributor of Acetium® capsules in Mongolia.

After the end of the reporting period, we signed a distributor agreement with Taiwanese Giraffes Pharmaceutical Company. The agreement entered into force immediately, giving Giraffes Pharma exclusive rights to distribute Acetium® capsules and Acetium® lozenge in Taiwan. Biohit Oyj signed a distribution agreement with Eastar Pharmaceuticals LLC, whichgains exclusive rights for the distribution of Acetium® lozenge in China. The Acetium® lozenge Chinese registration procedures and distribution channel preparations started immediately. In order to boost the sales and marketing of Biohit's antibodies to research institutes and the diagnostics industry, we signed agreements with R&D Systems China in China, Taiwan and Hong Kong. Meditecno Médicos e Sistemade Diagnóstico Lda. is our new distributor of diagnostics products in Portugal and Al Misbar Medical Technology Co. is our new distributor of diagnostics products in Jordania.

During the reporting period, we started the marketing of a new diagnostic test, Biohit Active B12, which allows the diagnosis of biologically active B12 vitamin deficiency from venous blood sample. The registration of Acetium® capsules in Mexico is delayed due to the organizational changes taking place in the local register authority. The GastroPanel® validation project for the Dynex Technologies DS2 – ELISA automated system has been completed. Dynex DS2 users can now run the GastroPanel®  test in accordance with a protocol validated by Biohit.'   

CONSOLIDATED KEY FIGURES

  4-6/2014 4-6/2013 1-6/2014 1-6/2013
Net sales (MEUR) 1.1 0.8 2.0 1.4
Operating profit/loss, continuing operations (MEUR) -1.3 -2.4 -2.4 -3.4
Profit/loss before taxes (MEUR) -1.2 -2.5 -2.2 -3.5
Profit/loss for the period, continuing operations (MEUR) -1.3 -2.5 -2.3 -3.5
Profit/loss for the period, discontinued operations (MEUR) 0.0 0.0 3.3 0.0
Profit/loss for the period, total (MEUR) -1.3 -2.5 1.0 -3.5
Average number of personnel 49 42 47 39
Number of personnel at the end of the period 49 45 49 45
Equity ratio (%) 84.7% 80.3% 84.7% 80.3%
Earnings per share, continuing operations (EUR) -0.09 -0.18 -0.16 -0.25
Earnings per share, discontinued operations (EUR)     0.23  
Shareholder equity per share (EUR) 1.03 1.77 1.03 1.77
Average number of shares during the period 13,857,241 13,692,736 13,834,958 13,654,164
Number of shares at the end of the period 13,985,593 13,795,593 13,985,593 13,795,593

REPORTING

Biohit's product portfolio consists of diagnostic tests, acetaldehyde-binding products, and monoclonal antibodies. All business is reported under a single segment, including liquid handling products, instruments and software.

NET SALES AND RESULT

January–June

Net sales grew by 50.9% compared with 1–6/2013.

The operating loss from continuing operations was EUR -2.4 million (EUR -3.4 million 1–6/2013). The result for continuing operations during the reporting period totalled EUR -2.3 million (EUR -3.5 million). In order to exploit the marked potential of our products and the resulting business growth, we must make substantial investments in building a distributor and partner network and supporting these partners.

The result for discontinued operations during the reporting period totalled EUR 3.3 million (EUR 0.0 million). In conjunction with the liquid handling business divestment in late 2011, EUR 3.5 million of the gains on the sale was not recognised due to the terms of the sale agreement and other factors related to the sale that remained open at the time. The amount was recognised on 31 March 2014, when the deal was closed.

The result for the reporting period totalled EUR 1.0 million (EUR -3.5 million).

Consolidated net sales and result for continued operations

  4-6/2014 4-6/2013 Change 1-6/2014 1-6/2013 Change 1-12/2013
Net sales MEUR 1.1 0.8 0.3 2.0 1.4 0.7 3.5
Change compared with the previous year (%) 39.3 %     50.9 %      
Operating income MEUR -1.3 -2.4 1.1 -2.4 -3.4 1.0 -5.9
Change compared with the previous year (%) 51.5 %            
Operating income (% of net sales) -113 %       -254 %   -170 %

The impact of currency exchange rates

During the reporting period, exchange rates did not have a significant influence, EUR 0.0 million (EUR 0.0 million).

BALANCE SHEET

On 30 June 2014, the balance sheet total was EUR 17.0 million (EUR 30.5 million) and the equity ratio was 84.7% (80.3%).

FINANCING

Biohit Oyj enjoys a strong financial position, which allows determined investments in an international distributor network as well as the development and commercialisation of new products. At the end of the reporting period, the company's financial assets totalled EUR 11.9 million (EUR 18.3 million).

RESEARCH AND DEVELOPMENT

R&D operations focused on improvements and further developments to existing innovations and products, and on their commercialisation. Biohit also employs external experts and subcontractors in its R&D operations. Development expenditure on the diagnostics business has not been capitalised. Research and development expenditure during the reporting period amounted to EUR 0.5 million (EUR 0.5 million).

Our development activities focused on the GastroPanel®  standardisation project and launch of ColonView, Biohit Active B12 and Biohit Calprotectin tests.

As part of our research activities we initiated a research project on smoking cessation (Acetium® lozenge as the research product), two comparative trials of the celiac quick test in overseas research institutes and a study assessing eradication of Helicobacter pylori infection, which will be continued in laboratory tests.

During the reporting period, we launched two clinical trials  for prevention  of migraine-type headache attacks (Acetium® capsules as the research product). In Brazil, having received the research permission from the hospital ethical committee, we initiated a comparative trial of the ColonView test, involving a sample of 500 colonoscopy patients. The ColonView test will be compared to another test type as the screening method for colorectal cancer.

INVESTMENTS

Gross investments during the reporting period totalled EUR 0.1 million (EUR 2.2 million).

PERSONNEL

During the reporting period, the average number of personnel employed by the Group was 49 (42 ) of whom 40 (31) were employed by the parent company and 9 (11) by its subsidiaries. At the end of the reporting period, the Group employed 49 (45) personnel, of whom 40 (34) were employed by the parent company and 9 (11) by the subsidiaries.

SHORT-TERM RISKS AND UNCERTAINTY FACTORS

Biohit’s key risks have to do with the investments required for business growth. There are risks involved in areas such as the success of clinical trials, new market areas, the selection and development of distribution channels, personnel recruitment, registration processes, product pricing, and the political decision-making affecting the progress of screening programmes. Significant short-term risks are associated with the selection of new market areas, the timing of expansion into selected markets, and product success in these markets. The recent increase in uncertainty factors associated with international politics may have an unfavourable impact on the company's business.

The duration of the product registration process is different in each market area, and affects the company's business development. It is not possible to accurately assess the time it takes to complete all registrations in the main markets and to begin generating net sales.

When investing liquid assets, the objective is to gain a return on investment with a minimum risk of equity loss. The investment portfolio consists of deposits, money market investments and corporate loans. A fundamental aspect in portfolio management is sufficient diversification across different asset classes, investment instruments and counterparties. Biohit conducts its investment activities with at least two partners.

Thanks to its wide customer base, Biohit does not materially depend on any individual customers or individual project deliveries, with the exception of GastroPanel®  sales in China, which currently represents a major business for Biohit. Most of the company’s business is conducted in euro, and the indirect effects of currency exchange rate fluctuations are considered minor.  

MAIN EVENTS IN THE REPORTING PERIOD

New product: Biohit Active B12 for diagnosis of B12 vitamin deficiency

During the reporting period, Biohit started the marketing of a new diagnostic test, which allows the diagnosis of B12 vitamin deficiency from venous blood sample. Vitamin B12 deficiency can occur in seemingly healthy people, and the risk increases with age. Unlike conventional tests, the new test does not measure the level of total B12 but the available active form of vitamin B12, holotranscobalamin, level in the blood. The new test is CE-IVD registered and at the time of market entry available in European countries.  

Biohit's Acetium® registration incomplete in Mexico

The registration of Acetium® capsules in Mexico is delayed due to the organizational changes taking place in the local register authority.

New distributor deals during the reporting period

During the reporting period, we continued to expand our distributor network. Bestbion dx GmbH was appointed as a quick tests distributor in Germany, Gulfmed Egypt was appointed as a quick tests distributor in Egypt and Gulf Orlando Medical Co. was appointed as a quick tests distributor in Kuwait. Aloris Vital, S.r.o. was appointed our diagnostics distributor in Slovakia and the Czech Republic. Ildengun Khoshuu Co., LTD was appointed the distributor of Acetium® capsules in Mongolia.

The GastroPanel®  validation project for the automated Dynex system completed

The GastroPanel®  validation project for the Dynex Technologies DS2 – ELISA automated system has been completed. DS2 users can now run the GastroPanel®  test in accordance with a protocol validated by Biohit. Automated Dynex DS2 systems have already been delivered to over 1,000 laboratories globally. The automated Dynex ELISA analyser, which utilises the vertical measurement method invented and developed by Professor Osmo Suovaniemi, enhances GastroPanel® 's availability and usability (for more information, visit www.biohithealthcare.com/about-us/history: Aggressive innovation and patenting strategy). With the help of an integrated system, small- and medium-sized laboratories can easily and cost-effectively add GastroPanel®  to their range of services.

Annual General Meeting

Biohit Oyj's Annual General Meeting (AGM) took place on Monday 14 April 2014. The AGM adopted the parent company's financial statements and the consolidated financial statements for 2013, and discharged the members of the Board of Directors and the Chief Executive Officer from liability.

Dividend payout

As proposed by the Board of Directors, the AGM decided that the loss for the financial period ended would be recorded in the profit and loss account. As proposed by the Board of Directors, the AGM decided that on the basis of the financial statements to be adopted for the financial period ended on 31 December 2013, a dividend of EUR 0.72 per each A share and EUR 0.7234 for each B share would be paid. The dividend was paid to shareholders recorded in the company's shareholder register on the matching day, 17 April 2014. The dividend was paid out on 28 April 2014.

Members of the Board of Directors

The AGM decided that the number of members of the Board of Directors would be five (5), and re-elected the following members to the Board until the end of the next AGM: Professor Osmo Suovaniemi, Professor Mikko Salaspuro, Commercial Counselor  Eero Lehti, and Seppo Luode, MSc (Engineering), as well as President and CEO Franco Aiolfi. A decision was made at the Annual General Meeting to pay a meeting fee of EUR 1,600 to the Chairman of the Board and a meeting fee of EUR 1,500 to other Board members.

Election of the auditor

Authorized public accountants PricewaterhouseCoopers Oy were elected as Biohit Oyj's auditors, with Authorized Public Accountant Pasi Karppinen as chief auditor, for a term expiring at the end of the next AGM.

Amendment to the Articles of Association

As proposed by the Board of Directors, the AGM decided to amend Article 3 of the Articles of Association so as to remove the provisions on the minimum and maximum amounts of share capital and shares. In addition, as proposed by the Board of Directors, the AGM decided to abolish par value in Article 4 of the Articles of Association.

The new wording of Article 3 of the Articles of Association is as follows:

"Article 3 Biohit Oyj's shares are divided into A series and B series shares. In the general shareholders’ meeting, one A series share entitles the holder to 20 votes, while one B series share entitles the holder to 1 vote.

In terms of dividends, B series shares receive dividends that are 2 (two) percentage points higher than A series shares in relation to the nominal values. In applying this provision, the share par value is considered to be EUR 0.17, which was the par value of the company share at the time when the company decided to abolish the par value of shares.

In the case of dissolution of the company due to a merger or some other reason, holders of A and B series shares have an equal right to merger consideration or other compensation payable due to dissolution.

The shares of the company are listed in a book-entry security system.

An A series share can be converted, upon the request of its holder, into a B series share by a decision of the Board of Directors, entitling the holder to receive one B series share for one A series share."

As proposed by the Board of Directors, the AGM decided that Article 4 of the Articles of Association will be replaced by a provision specifying that the company's shares do not have par value.

The new wording of Article 4 of the Articles of Association is as follows: "Article 4 The company's shares do not have par values."

Authorization of the Board of Directors to decide on the issue of shares and the special rights entitling to shares

The AGM authorized the Board of Directors to decide on the issue of shares and the special rights entitlement to shares, referred to in Chapter 10, Section 1 of the Limited Liability Companies Act, as follows:

The maximum number of new B series shares to be issued pursuant to the special rights is 3,000,000, which corresponds to approximately 30% of the company's B series shares.

The Board of Directors decides on all terms and conditions regarding the issue of shares and the issue of special rights. The issue of shares and the issue of special rights entitlement to the receipt of shares can occur in deviation from the subscription right of shareholders (special issue).

Such an authorization remains valid for three years from the resolution of the AGM.

The printed version of Biohit's 2013 Annual Report was distributed to the shareholders at the AGM. All decisions taken at the shareholder meeting were unanimous. The minutes of the AGM are available to shareholders on the company's website at www.biohithealthcare.com/investors.

MAJOR EVENTS AFTER THE END OF THE PERIOD

New distributor agreements

After the end of the reporting period, we signed a distributor agreement with Taiwanese Giraffes Pharmaceutical Company. The agreement entered into force immediately, giving Giraffes Pharma exclusive rights to distribute Acetium® capsules and Acetium® lozenge in Taiwan. Biohit Oyj signed a distribution agreement with Eastar Pharmaceuticals LLC, whichgains exclusive rights for the distribution of Acetium® lozenge in China. The Acetium® lozenge Chinese registration procedures and distribution channel preparations started immediately. In order to boost the sales and marketing of Biohit's antibodies to research institutes and the diagnostics industry, we signed agreements with R&D Systems China in China, Taiwan and Hong Kong. Meditecno Médicos e Sistemade Diagnóstico Lda. is our new distributor of diagnostics products in Portugal and Al Misbar Medical Technology Co. is our new distributor of diagnostics products in Jordania.

Chinese Health Associations give consensus clause on early gastric cancer screening with GastroPanel®  entity

Chinese health associations The Chinese Society of Digestive Endoscopy and The Society of Ontological Endoscopy of Chinese Anti-Cancer Association have given a consensus clause regarding screening, endoscopic diagnosis and treatment of early gastric cancer in China. Consensus clause recommends serum screening with Pepsinogen-1, Pepsinogen-2, Gastrin-17 and Helicobacter pylori tests that together form GastroPanel® entity.

SHARES AND SHAREHOLDERS

Biohit Oyj's shares are divided into A series and B series shares. There are 2,975,500 A series shares and 11,010,093 B series shares, totalling 13,985,593 shares. A series shares confer 20 votes per share and B series shares confer 1 vote per share. Supposing that the market capitalization value for A and B series shares is equal, the total market capitalization value at the end of the period was EUR 85.9 million (EUR 86.8 million on 30 June 2013).

Biohit Oyj's B series shares are quoted on NASDAQ OMX Helsinki in the Small cap/Healthcare group under the code BIOBV.  

BIOBV/NASDAQ OMX Helsinki 1-6/2014 1-6/2013
High (EUR) 8.17 9.10
Low (EUR) 5.42 4.00
Average (EUR) 6.85 6.54
Latest (EUR) 6.14 6.29
Turnover (EUR) 17,286,862 45,435,364
Turnover volume 2,522,648 6,946,721

Shareholders

At the end of the reporting period on 30 June 2014, the company had 6,607 shareholders (6,126 on 31 December 2013). Private households held 78.1% (77.6%), companies 20.1% (20.6%), public sector organizations 0.0% (0.0%) and non-profit organizations 0.0% (0.0%). Foreign ownership or nominee registrations accounted for 1.7% (1.7%) of shares.

Further information on the shares, major shareholders, and management shareholdings is available on the company's website at www.biohithealthcare.com/investors.

ACCOUNTING PRINCIPLES

This interim report has been prepared in accordance with the requirements of the IAS 34 standard.

All business operations are presented as one segment. Biohit Oyj has applied the same accounting principles in preparing this interim report as for its financial statements of 2013. The IFRS standards that came into effect in 2014 did not have a material impact on the accounting principles.

All the figures in the interim report have been rounded up or down, due to which the sums of figures may deviate from the sum total presented.

The figures in this interim report have not been audited.  

CONSOLIDATED INCOME STATEMENT

MEUR 4-6/ 2014 4-6/ 2013 Change 1-6/ 2014 1-6/ 2013 Change 1-12/ 2013
Net sales 1.1 0.8 0.3 2.0 1.4 0.6 3.5
Materials and services -0.5 -0.4 -0.1 -0.8 -0.8 0.0 -1.7
Gross margin 0.6 0.4 0.2 1.2 0.6 0.6 1.8
Other operating income 0.0 0.0 0.0 0.1 0.0 0.1 0.0
Sales and marketing -0.5 -0.6 0.1 -1.0 -1.0 0.0 -2.3
Administration -0.8 -1.9 1.1 -1.8 -2.5 0.7 -4.3
Production and product development -0.5 -0.3 -0.2 -1.0 -0.5 -0.5 -1.0
Share of profit/loss in Joint Venture 0.0     0.0      
Operating profit/loss, continuing operations -1.3 -2.4 1.2 -2.4 -3.4 1.0 -5.9
Financial income 0.1 0.0 0.0 0.2 0.0 0.2 0.2
Financial expenses 0.0 0.0 0.0 0.0 -0.1 0.1 -0.2
Profit/loss before taxes -1.2 -2.5 1.2 -2.2 -3.5 1.3 -5.9
Income taxes -0.1 0.0 -0.1 -0.1 0.0 -0.1 0.0
Income for the period, continuing operations -1.3 -2.4 1.2 -2.3 -3.5 1.2 -5.9
Income for the period, discontinued operations 0.0 0.0 0.0 3.3 0.0 3.3 0.0
Income for the period, total -1.3 -2.5 1.2 1.0 -3.5 4.5 -5.9
Other comprehensive income after taxes              
Other comprehensive income to be reclassified to profit or loss in subsequent periods              
Available-for-sale financial assets 0.1 0.0 0.1 0.2 0.0 0.2 0.1
Translation differences 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Other comprehensive income to be reclassified to profit or loss in subsequent periods, total 0.1 0.0 0.1 0.2 0.0 0.2 0.1
Total comprehensive income for the period -1.2 -2.5 1.3 1.1 -3.5 4.6 -5.8

Earnings per share calculated from earnings attributable to equity holders of the parent company

  1-6/2014 1-6/2013 1-12/2013
Undiluted earnings per share, continuing operations (EUR) -0.17 -0.25 -0.43
Undiluted earnings per share, discontinued operations (EUR) 0.24    
Diluted earnings per share, discontinued operations (EUR) 0.23    

CONSOLIDATED BALANCE SHEET

MEUR 30 June 2014 30 June 2013 31 Dec. 2013
ASSETS      
NON-CURRENT ASSETS      
Intangible assets 1.9 2.3 1.7
Tangible assets 0.5 0.6 0.5
Share in Joint Venture 0.9   1.0
Other financial long-term assets 0.0 7,8* 1.0
Deferred tax assets 0.0 0.0 0.0
Total non-current assets 3.3 10.7 4.2
       
CURRENT ASSETS      
Inventories 0.8 0.7 0.6
Trade and other receivables 0.9 0.8 7.7
Other financial short-term assets 11.4 18.0 15.2
Cash and cash equivalents 0.6 0.3 0.5
Total current assets 13.7 19.8 24.1
       
TOTAL ASSETS 17.0 30.5 28.3
       
SHAREHOLDERS' EQUITY AND LIABILITIES      
SHAREHOLDERS' EQUITY ATTRIBUTABLE TO THE OWNERS OF THE PARENT COMPANY      
Share capital 2.4 2.3 2.3
Invested unrestricted equity fund 1.5 1.1 2.8
Translation differences 0.0 0.0 0.0
Retained earnings 10.5 21.0 17.3
Total shareholders' equity 14.4 24.5 22.5
       
NON-CURRENT LIABILITIES      
Deferred tax liabilities 0.2 0.0 0.2
Other liabilities 0.0 0.0 0.0
Total non-current liabilities 0.2 0.0 0.2
       
CURRENT LIABILITIES      
Trade payables 0.3 0.6 0.3
Total interest-bearing liabilities 0.3 0.4 0.4
Tax liabilities 0.1 0.0 0.1
Other liabilities 0.8 5.0 3.9
Deferred gain 0.9 0.0 1.0
Total current liabilities 2.4 6.0 5.6
       
Total liabilities 2.6 6.0 5.8
       
TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES 17.0 30.5 28.3

* Items include EUR 6.8 million in receivables from a business transaction completed in 2011; the funds were placed in an escrow account. The funds placed in the escrow account were released on 31 March 2014.

STATEMENT OF CHANGES IN EQUITY

Consolidated statement of changes in equity on 30 June 2014

MEUR Share capital Translation differences Invested unrestricted equity fund Retained earnings Shareholders' equity
Shareholders' equity 1 Jan 2014 2.3 0.0 2.8 17.3 22.5
Distribution of dividend       -10.0 -10.0
Capital repayment          
Direct share issue          
Share-based payments     -1.6 2.0 0.4
Exercise of share options 0.0   0.4   0.4
Total comprehensive income for the period   0.0   1.1 1.1
Shareholders' equity June 30, 2014 2.4 0.0 1.5 10.5 14.4

Consolidated statement of changes in equity on 30 June 2013

MEUR Share capital Translation differences Invested unrestricted equity fund Retained earnings Shareholders' equity
Shareholders' equity 1 Jan 2013 2.3 0.0 3.2 30.0 35.5
Distribution of dividend       -6.8 -6.8
Capital repayment     -3.2   -3.2
Share issue to Euroclone     1.1   1.1
Share-based payments          
Exercise of share options       1.3 1.3
Total comprehensive income for the period   0.0   -3.5 -3.5
Shareholders' equity June 30, 2013 2.3 0.0 1.1 21.0 24.5

CASH FLOW STATEMENT

MEUR 1-6/2014 1-6/2013 1-12/2013
CASH FLOW FROM OPERATING ACTIVITIES      
Profit for the period 1.0 -3.5 -5.9
Adjustments -2.9 1.4 1.9
       
Change in working capital -0.1 -2.0 -0.5
Interest paid and payments on other operating financial expenses 0.0 0.0 -0.2
Interest received 0.2 0.0 0.3
Realised exchange rate gains and losses 0.0 0.0 0.0
Income taxes paid 0.0 0.0 0.1
Net cash flow from operating activities -1.9 -2.0 -4.4
       
CASH FLOW FROM INVESTMENTS      
Investments in tangible and intangible assets -0.2 -0.1 -0.5
Revenue from disposal of tangible and intangible assets 0.0 0.0 0.0
Capital gain from the sale of liquid handling business 6.8    
Net investments in funds and deposits 5.0 12.1 15.1
Net cash flow from investments 11.7 12.1 14.6
       
CASH FLOW FROM FINANCING ACTIVITIES      
Rights issue 0.4 0.0 0.0
Dividend payout -10.0 -6.8 -6.8
Repayment of capital 0.0 -3.2 -3.2
Repayment of loans -0.1 0.0 0.0
Net cash flow from financing activities -9.7 -10.0 -10.0
       
Increase (+)/decrease (-) in cash and cash equivalents 0.1 0.1 0.2
Cash and cash equivalents at the beginning of the period 0.5 0.2 0.2
Effect of exchange rates on cash and cash equivalents 0.0 0.0 0.0
Cash and cash equivalents at the end of the period 0.6 0.3 0.5

RELATED PARTY TRANSACTIONS

There have been no noticeable changes in related party transactions during the reporting period.

Biohit Oyj B series shares subscribed with Stock Options I and II 2013

A total of 160,000 new Biohit Oyj B series shares were subscribed with stock options I 2013 and II 2013 during May 21 – June 2,  2014. These shares were entered into the trade register on June 12, 2014, as of which date the new shares established equal shareholder rights with the company's existing B series shares. Public trading began on NASDAQ OMX Helsinki as of June 13, 2014, together with the existing B series shares.

The share subscription price was EUR 2.2766 per share with stock options I 2013 and II 2013. The entire subscription price of EUR 364,256 was credited to the reserve for invested non-restricted equity, and the company share capital remained unchanged. The shares have no nominal value.

After the subscription the total number of Biohit Oyj shares rose to 13,985,593 shares (13,825,593) and the number of B series shares rose to 11,010,093 shares (10,850,093). The new shares correspond to a percentage of 1.1% of Biohit Oyj's total number of shares and 0.23% of the voting rights after registration.

The share subscription period for stock options I 2013A began on June 1, 2014, and all the available 100,000 shares were subscribed. The share subscription period for stock options II 2013 began on July 1, 2013, and will end on June 30, 2015. The option schemes are based on the Biohit Oyj board resolution of June 19, 2013, and the Annual General Meeting authorization of April 13, 2011. The terms and conditions of the option schemes, with additional information, are available on the Biohit Oyj website at www.biohithealthcare.com.

To exercise their stock options, holders must have paid the subscription price in accordance with the option scheme (EUR 3 or EUR 3 less the dividend depending of the timing). Holders exercising their stock options are liable to pay income tax for the stock option income.

COLLATERAL, CONTINGENT LIABILITIES, AND OTHER COMMITMENTS

MEUR 1-6/2014 1-6/2013 1-12/2013
       
Collateral granted on behalf of the parent company      
Corporate mortgages 0.0 0.0 0.0
       
Collateral granted on behalf of the subsidiaries      
Guarantees 0.0 0.0 0.0
       
Other liabilities      
Leasing commitments      
Due for payment in less than one year 0.1 0.1 0.1
Due for payment in more than one year but less than five years 0.0 0.1 0.1
Due for payment in more than five years 0.0 0.0 0.0
Total 0.1 0.2 0.1
       
Other rental commitments      
Due for payment in less than one year 0.2 0.2 0.2
Due for payment in more than one year but less than five years 0.2 0.3 0.3
Due for payment in more than five years 0.0 0.0 0.0
Total 0.4 0.6 0.5
Other liabilities, total 0.5 0.8 0.6
       
Commitments and contingencies, total 0.5 0.8 0.6

NEXT FINANCIAL REPORT

The interim report for January–September 2014 (Q3) will be published on Thursday, 23 October 2014, at 9:30 am.

Helsinki, 20 August 2014

Biohit Oyj Board of Directors  

Additional information: CEO Semi Korpela, Biohit Oyj tel. +358 9 773 861 investor.relations@biohit.fi www.biohithealthcare.com

Biohit Oyj in Brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission ‘Innovating for Health’ means that we provide innovative products and services to promote research and early diagnostics. Biohit is headquartered in Helsinki and has subsidiaries in Italy and the UK. Biohit’s B series shares (BIOBV) are quoted on NASDAQ OMX Helsinki under Small cap/Healthcare. www.biohithealthcare.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Envision and Tsinghua Propel Climate Innovation at COP31

Updated Category News Views 87

Collaborating for a Greener Future On the bustling stage of COP31 in Antalya, Turkey, Envision Energy and Tsinghua University teamed up with the Global Alliance of Universities on Climate (GAUC) to showcase a bold agenda. Their focus transcends mere dialogue, pushing for actionable climate solutions anchored in technological innovation, academic synergy, and the dynamism...

Continue Reading
A Teen's Opera Encounter Inspires Decades of Passion

Updated Category News Views 0

Unraveling a Lifelong Opera Obsession Back in the dog-eared days of 1970, a teenager waltzed into the Metropolitan Opera and stumbled onto a passion that'd pulse alongside him for over half a century. Now, David E. Lapin rolls out his personal chronicle, 'A Sound Obsession: Fifty-Five Years of Opera at the Met.' Folks, we’re diving into a cultural tapestry that’s...

Continue Reading
Jones Soda Expands into Nutrition with UCAN Deal

Updated Category News Views 145

Well, Jones Soda Co. (CSE: JSDA) is stirring the pot with its recent move to acquire the UCAN functional nutrition assets. Popped the news on November 12, 2026, and it turns out they've shelled out a cool $700,000 in cash and taken on $500,000 in liabilities for the privilege. This isn't some casual shuffle of dollars and cents—this one's a strategic gambit aimed at...

Continue Reading
Ampace Focuses on Battery Safety Standards at RE+ 2026

Updated Category News Views 146

Battery Safety Takes Center Stage No mystery here: the safety of our beloved lithium-ion batteries is crucial, especially as AI data centers sprout like weeds. At RE+ 2026, Ampace is putting its chips on the table by spotlighting this hot topic. Dr. Drew Feng, their Chief Safety Officer, is set to reveal the big guns: findings from the PU100 large-scale fire test. Mark...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 279

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
Daqo New Energy Faces Key Investor Meeting in December

Updated Category News Views 88

Spotlight on December's Agenda for Daqo Shareholders Who'd have thought we'd be looking at another year end with the same burning energy interests? Daqo New Energy Corp. (NYSE: DQ) is setting up for its annual general meeting (AGM) dated December 10, 2026. Mark your calendars, because these gatherings can be more than just straightforward affairs; sometimes they reveal...

Continue Reading
Segway Powersports Dominates Baja 1000 with Class 2 Sweep

Updated Category News Views 86

Catching the eye of any betting man, Segway Powersports has turned its maiden outing at the relentless SCORE Baja 1000 into a rousing victory. Their arrival on this unforgiving stage with a one-two in Class 2 isn't just a lucky roll—you don't chance upon podium sweeps in such gritty contests. Dissecting the Drive: Commitment and Coordination Unfolding across Baja's...

Continue Reading
Bacterial Breakthrough in Cancer Therapy: Game Changer?

Updated Category News Views 7

Blurring Lines Between Bugs and Biotech Well, wouldn't you know it, the eggheads over at Jeonbuk National University in South Korea are at it again, pushing the boundaries of what these little bacterial buggers can do. This time, they’ve had a crack at cancer therapy, using engineered Salmonella to pack a double punch against breast cancer in mice. Now, if that ain't...

Continue Reading
SwitchBot's Hub 4: A Step Toward a Connected Future

Updated Category News Views 37

Turning a House Into a Smart Home Haven Out of Tokyo and onto the world stage, SwitchBot's got something new cooking that might just shake up the smart home scene. They've launched the Hub 4, a gadget that's like the Swiss Army knife of home control. For those who like things simple, this is a one-hub-to-rule-them-all kind of deal. 101,000 Reasons to Notice Now, they...

Continue Reading
Nord Anglia Schools Shine with 13 Tes Awards Nominations

Updated Category News Views 87

Nord Anglia's Moment of Glory at Tes Awards You think you know the big players in the educational game? Well, guess again. Nord Anglia's come out swinging with a whopping 13 finalist nominations at the 2026 Tes Awards for International Schools. It ain't easy making waves in the education sector, but these folks are showing they've got what it takes to turn heads, not just...

Continue Reading

Top 5 Most Recently Viewed Articles

Piper Sandler Welcomes John Kerins to Healthcare Team

Updated Category News Views 218

Piper Sandler Expands Healthcare Investment Banking Expertise Piper Sandler Companies (NYSE: PIPR), a prominent name in investment banking, is excited to announce a significant addition to their healthcare investment banking team with the hiring of John Kerins as a managing director. This strategic move reflects the firm’s commitment to strengthening its presence in the...

Continue Reading
Exploring North America's Last Mile Delivery Growth and Trends

Updated Category News Views 346

Exploring North America's Last Mile Delivery Growth and Trends The last mile delivery market in North America is poised for significant growth over the next few years. Experts estimate that this market could expand by USD 14.9 billion between 2025 and 2029. This impressive growth is being driven primarily by the increasing demand for business-to-consumer (B2C) e-commerce....

Continue Reading
Mastercard Marks 20 Years on NYSE with Digital Shift

Updated Category News Views 39

A Landmark Moment at the NYSE for Mastercard Ah, another day in the whirlwind of the stock universe, where birthdays are celebrated with the finesse of boardroom discussions. Mastercard (NYSE: MA) is taking a well-deserved spotlight as it cheers two decades since it hit the seal of the New York Stock Exchange. Back on May 26th, it wasn't just business as usual. Nope, they...

Continue Reading
Insights into the Expanding Network of China-Europe Freight Trains

Updated Category News Views 236

The Rise of China-Europe Freight Trains Recently, a significant milestone was reached when the 110,000th China-Europe freight train departed from Jiaozhou Station, fully loaded with various goods such as electronic displays and household appliances. This service has now transported goods worth over USD 450 billion, showcasing its crucial role in global trade. The Journey...

Continue Reading
Netflix Investors Encouraged to Report Losses Amid Investigation

Updated Category News Views 217

Investigation Focus on Netflix, Inc. (NASDAQ: NFLX) Recently, significant scrutiny has emerged surrounding Netflix, Inc. (NASDAQ: NFLX), as Edelson Lechtzin LLP, a prominent national law firm known for handling class action lawsuits, initiates an investigation into potential violations of federal securities laws. This inquiry seeks to determine whether Netflix and certain...

Continue Reading